Zoetis Inc. (NYSE:ZTS) Stock Has Consensus Target Price of $98.07

Zoetis Inc. (NYSE:ZTS) has been given an average rating of “Hold” by the twenty research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $98.40.

A number of equities analysts have commented on the stock. BNP Paribas Exane reduced their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. William Blair cut shares of Zoetis from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 6th. Jefferies Financial Group cut shares of Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the company from $103.00 to $83.00 in a research note on Tuesday, October 20th. Morgan Stanley set a $85.00 price target on shares of Zoetis in a report on Friday, August 7th. Finally, UBS Group lifted their price target on shares of Zoetis from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Tuesday.

Zoetis Stock Down 0.7%

Shares of NYSE:ZTS opened at $77.67 on Monday. Zoetis has a 52-week low of $68.77 and a 52-week high of $146.11. The stock has a market cap of $32.10 billion, a P/E ratio of 12.80, a PEG ratio of 1.20 and a beta of 0.74. The business has a fifty day moving average of $74.91 and a two-hundred day moving average of $94.11. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts expect that Zoetis will post 6.15 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is presently 34.93%.

Institutional Investors Weigh In On Zoetis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Flossbach Von Storch SE purchased a new position in shares of Zoetis during the 2nd quarter worth approximately $302,601,000. BlackRock Inc. grew its stake in shares of Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after buying an additional 3,845,869 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. acquired a new stake in shares of Zoetis in the first quarter valued at $286,660,000. Southpoint Capital Advisors LP grew its stake in shares of Zoetis by 340.0% in the first quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock valued at $260,062,000 after buying an additional 1,700,000 shares in the last quarter. Finally, Carmignac Gestion purchased a new stake in shares of Zoetis in the 2nd quarter valued at $113,230,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.